Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


UBS Downplays G7 CGM Sensor Concerns, Affirms DexCom’s Inc. (DXCM) ‘Buy’ Rating

2025-09-29
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated the bullish stance even as the company faces concerns over its G7 continuous glucose monitoring sensor. The device has come […]

Biolinq gets FDA de novo nod for intradermal glucose sensor

2025-09-26
The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin.

1 Growth Stock Down 40% to Buy Hand Over Fist Right Now

2025-09-23
It is dealing with some short-term issues, but its prospects remain bright.

S&P 500 Gains and Losses Today: Paramount Surges Amid Deal Buzz, Apple Rises as iPhone 17 Goes on Sale

2025-09-19
More details about a possible deal in the media industry contributed to another leg up for Paramount and Warner Bros Discovery, while a report from a short seller sent shares of DexCom sharply lower.

Stock Market Today: Dow, S&P Aim For New Highs; Gold Stocks Shine (Live Coverage)

2025-09-19
Major stock indexes rise Friday as Wall Street awaits news from President Donald Trump's call with China's Xi Jinping.

Why DexCom (DXCM) Shares Are Trading Lower Today

2025-09-19
Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring device, questioned its accounting, and highlighted an executive exodus.

Stock Market Today: Dow Falls From Highs Amid Trump-Xi Call; Why Uber Is Spiking (Live Coverage)

2025-09-19
Major stock indexes turned mixed in the stock market today as Wall Street await news from President Trump's call with China's Xi Jinpingf

Stock Market Today: Dow Hits Highs After Trump, Xi Talk; Cathie Wood Unloads AI Stock (Live Coverage)

2025-09-19
Stock Market Today: Dow Hits Highs After Trump, Xi Talk; Cathie Wood Unloads AI Stock (Live Coverage)

Smart Medical Devices Market Size to Reach $180.4 Billion by 2033 - Strategic Growth Opportunities in Chronic Disease Management, Digital Health, and Connected Care

2025-09-19
The Smart Medical Devices Market Size valued at US$ 61.7 billion in 2024, is projected to reach US$ 180.4 billion by 2033, expanding at a CAGR of 12.8% (2025–2033), according to the latest report from DataM Intelligence.

Stock Market Today: Dow Ticks Up During Trump-Xi Call; Tesla Upgraded (Live Coverage)

2025-09-19
The Dow Jones index dropped Friday during the Trump-Xi phone call. Tesla stock rallied on an analyst upgrade.